Burosumab for the Treatment of Tumor‐Induced Osteomalacia

Tumor‐induced osteomalacia (TIO) is caused by phosphaturic mesenchymal tumors producing fibroblast growth factor 23 (FGF23) and is characterized by impaired phosphate metabolism, skeletal health, and quality of life. UX023T‐CL201 is an ongoing, open‐label, phase 2 study investigating the safety and...

Descripción completa

Detalles Bibliográficos
Autores principales: Jan de Beur, Suzanne M, Miller, Paul D, Weber, Thomas J, Peacock, Munro, Insogna, Karl, Kumar, Rajiv, Rauch, Frank, Luca, Diana, Cimms, Tricia, Roberts, Mary Scott, San Martin, Javier, Carpenter, Thomas O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247961/
https://www.ncbi.nlm.nih.gov/pubmed/33338281
http://dx.doi.org/10.1002/jbmr.4233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247961/
https://www.ncbi.nlm.nih.gov/pubmed/33338281
http://dx.doi.org/10.1002/jbmr.4233

Ejemplares similares